Who
Pascal Deschatelets
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Apellis Pharmaceuticals.
In numbers
- Trades disclosed
- 200
- Buys
- 0
- Sells
- 42
- Bought
- $0
- Sold
- $32.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 Feb 2018
- Last trade
- 14 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code U | —1,177,222 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —4,909 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —3,372 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —11,284 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —25,840 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —108,622 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —82,500 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —110,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —95,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,974 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —56,250 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —41,250 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,845 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —9,805 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —41,250 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —108,622 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —82,500 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —110,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —95,000 | filing |
News
No headline names them, or the companies they trade most, lately.